aibioCGEN Compugen Ltd.
Compugen (CGEN) news
Compugen Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CGEN, recorded under Israel. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Compugen news
We have not published a story on Compugen yet. When there is news, it will appear here.
Compugen annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $72.8 million | $27.9 million |
| Research and development | $22.8 million | $24.8 million |
| Net income (loss) | $35.3 million | -$14.2 million |
| Cash from operations | $31.6 million | $49.6 million |
| Cash and equivalents | $90.6 million | $18.2 million |
| Short-term investments | $9.3 million | $23.6 million |
Questions about Compugen
What is the ticker symbol of Compugen?
Compugen Ltd. trades under the ticker CGEN on NASDAQ.
Where is Compugen listed?
Compugen Ltd. is listed on NASDAQ. Our directory also records these other listings: TASE:CGEN.
What is the SEC CIK of Compugen?
The SEC Central Index Key (CIK) for Compugen Ltd. is 1119774. Its filings are on SEC EDGAR.
How many shares does Compugen have outstanding?
94,553,191 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-02.
Which country or territory is Compugen listed under?
Our directory records Compugen Ltd. under Israel.
What does Compugen do?
Our directory classifies Compugen Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Compugen?
The ISIN recorded for Compugen Ltd. is IL0010852080.
Does aibio.space cover Compugen?
aibio.space lists Compugen Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Compugen incorporated?
SEC records list its state or country of incorporation as L3.
What was Compugen's revenue last year?
$72.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Compugen profitable?
Compugen Ltd. reported net income of $35.3 million for the fiscal year ended Dec 31, 2025, and generated $31.6 million of cash from operations, per its annual report to the SEC.
How much does Compugen spend on research and development?
$22.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Compugen have?
$99.9 million in cash and short-term investments at Dec 31, 2025, per its 20-F.
Is Compugen a smaller reporting company?
SEC records list Compugen Ltd.'s filer category as: Accelerated filer.
Where is Compugen headquartered?
SEC records list its business address as 26 HAROKMIM STREET, HOLON, Israel, 5885849.
Investor discussion: Compugen
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Compugen Ltd
- CIK
- 1119774
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- CGEN (Nasdaq)
- State or country of incorporation
- L3
- Fiscal year ends
- December 31
- Filer category
- Accelerated filer
- Business address
- 26 HAROKMIM STREET, HOLON, Israel, 5885849
- Phone
- 011-972-3-765-8585
- Shares outstanding
- 94,553,191 as of 2025-12-31 (20-F filed 2026-03-02)
Recent filings
Listing details
- Company
- Compugen Ltd.
- Ticker
- CGEN
- Listing
- NASDAQ
- Country or territory
- Israel
- Business scope
- Biotechnology
- ISIN
- IL0010852080
- Other listed symbols
- TASE:CGEN
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction